To include your compound in the COVID-19 Resource Center, submit it here.

Local advantage

Theravance nears key inflection point for its first localized immunology candidate

Theravance Biopharma Inc. is reaching a key inflection point for the first candidate to emerge from its program to develop me-better immunology therapies that act locally and avoid systemic side effects.

The company will report new data by mid-year on TD-1473, an oral pan-Janus kinase (JAK) inhibitor for ulcerative colitis (UC) that is designed to restrict its activity to the small and large intestines and metabolize quickly in the blood stream to avoid systemic circulation.

While the ongoing Phase Ib trial of TD-1473 is not powered to demonstrate efficacy, preliminary data reported in August from the first cohort of UC patients showed the candidate induces biologic activity in the colon without exerting immunosuppressive systemic side effects observed with marketed JAK inhibitors, which result in an increased risk of opportunistic

Read the full 1294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers